



Supporting Information

for

Copper-catalyzed domino cyclization of anilines and cyclobutanone oxime: a scalable and versatile route to spirotetrahydroquinoline derivatives

Qingqing Jiang, Xinyi Lei, Pan Gao and Yu Yuan

Beilstein J. Org. Chem. **2025**, *21*, 749–754. doi:10.3762/bjoc.21.58

Experimental procedures, characterization data for all new compounds, and NMR spectra of products


Table of contents

1. General information.....	S2
2. The synthesis of cyclobutanone oxime ^[1]	S2
3. Reaction and method of cyclobutanone oxime with aniline	S3
4. Gram scale reaction	S4
5. Characterization data for spirotetrahydroquinoline derivatives	S5
6. References	S37
7. ¹ H and ¹³ C NMR spectra	S38

1. General information

All new compounds were fully characterized. All reactions and manipulations involving air-sensitive compounds were performed using standard Schlenk techniques. Anhydrous MeCN was purchased from Annaiji Chemical and was used as received. ^1H and ^{13}C NMR spectra were recorded on an Agilent DD2 400 MHz spectrometer. The chemical shifts in ^1H NMR spectra were recorded relative to CDCl_3 (δ 7.26). The chemical shifts in ^{13}C NMR spectra were recorded relative to CDCl_3 (δ 77.0). The high-resolution mass spectral (HRMS) data were obtained on a quadrupole-type Bruker Dalton MAXIS (APCI). Gas chromatography analyses were conducted with a Shimadzu GC-2014 equipped with ULBON HR-1 glass capillary column (Shinwa Chemical Industries) and an FID detector. Unless otherwise noted, materials obtained from commercial suppliers were used without further purification.


2. The synthesis of cyclobutanone oxime^[1]



To a mixture of hydroxylamine hydrochloride (1.2 equiv), sodium acetate (2.2 equiv), methanol (100mL) in a 250-mL two-necked flask was added cyclobutanone (1.0 equiv) and the mixture was stirred at 75°C for 12 h. The reaction mixture was cooled to room temperature and then methanol


was removed under vacuum and the resulting mixture was extracted with diethyl ether. The organic layer was washed with water and dried over MgSO_4 . The solvent was removed under reduced pressure and the crude material was subjected to column chromatography to afford cyclobutanone oxime in 95% yield.^[1]

3. Reaction and method of cyclobutanone oxime with aniline



A dried straight reaction tube was charged with **1** (0.4 mmol), **2** (0.2 mmol), and $\text{Cu}(\text{CF}_3\text{COO})_2$ (11.58 mg, 20 mol %), then dried *n*-hexane (2 mL) was added by using a syringe. The reaction mixture was stirred at 80°C for 12 h. After quenching the reaction with aqueous NH_4Cl (2 mL), the crude product was extracted with ethyl acetate (3×10 mL). The combined organic phases were dried over anhydrous Na_2SO_4 and concentrated under vacuum. The residue was purified by flash chromatography on neutral alumina to give the desired product **3**.


4. Gram scale reaction



A dried two-necked flask was charged with **1a** (10 mmol), **2a** (5 mmol), and $\text{Cu}(\text{CF}_3\text{COO})_2$ (145 mg, 20 mol %), then dried *n*-hexane (100 mL) was added by using a syringe. The reaction mixture was stirred at 80 °C for 12 h. After quenching the reaction with aqueous NH_4Cl (20 mL), the crude product was extracted with ethyl acetate (3×10 mL). The combined organic phases were dried over anhydrous Na_2SO_4 and concentrated under vacuum. The residue was purified by flash chromatography on neutral alumina to give the desired product **3aa** (yellow solid, 1.2 g, 82%).

5. Characterization data for spirotetrahydroquinoline derivatives


(8b'*S*)-*N*-Phenyl-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3aa)^[2]



3aa, 92%

The general procedure was applied to aniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow solid (27 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.32 (dd, *J* = 7.6, 1.5 Hz, 1H), 7.05 (td, *J* = 7.3, 1.1 Hz, 3H), 6.71 (td, *J* = 7.5, 1.2 Hz, 1H), 6.65 (td, *J* = 7.7, 1.1 Hz, 2H), 6.48 (dd, *J* = 8.7, 1.1 Hz, 2H), 4.05 (s, 2H), 2.99 (t, *J* = 8.5 Hz, 1H), 2.39 – 2.30 (m, 1H), 2.20 (dddd, *J* = 11.5, 9.6, 4.6, 1.0 Hz, 1H), 2.05 – 1.83 (m, 5H), 1.77 – 1.68 (m, 1H), 1.68 – 1.58 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 145.77, 142.98, 128.79, 127.63, 127.36, 126.94, 118.92, 117.54, 115.37, 56.50, 54.77, 50.45, 37.83, 37.52, 33.84, 15.49, 12.66.


7'-Fluoro-*N*-(4-fluorophenyl)-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ba)^[2]



3ba, 62%

The general procedure was applied to 4-fluoroaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow liquid (21 mg, 62% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.05 (dd, *J* = 9.7, 3.0 Hz, 1H), 6.80 – 6.73 (m, 3H), 6.58 (dd, *J* = 8.7, 4.7 Hz, 1H), 6.41 – 6.35 (m, 2H), 3.92 (s, 2H), 2.88 – 2.78 (m, 1H), 2.24 – 2.13 (m, 2H), 2.06 – 1.88 (m, 3H), 1.83 – 1.72 (m, 3H), 1.61 (dtd, *J* = 17.2, 8.9, 8.4, 3.0 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 157.96, 155.61, 141.70, 139.28, 129.12, 116.77, 116.32, 115.40, 114.43, 112.96, 57.05, 55.08, 50.23, 37.63, 37.49, 33.56, 15.47, 12.63.


7'-Chloro-*N*-(4-chlorophenyl)-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ca)^[2]



3ca, 80%

The general procedure was applied to 4-chloroaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow solid (29 mg, 80% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.24 (d, *J* = 2.5 Hz, 1H), 7.00 (dd, *J* = 8.7, 2.1 Hz, 3H), 6.57 (d, *J* = 8.5 Hz, 1H), 6.40 – 6.33 (m, 2H), 4.21 (s, 1H), 4.01 (s, 1H), 2.86 (t, *J* = 8.5 Hz, 1H), 2.28 – 2.15 (m, 2H), 2.00 (ddt, *J* = 14.2, 11.5, 4.4 Hz, 2H), 1.95 – 1.81 (m, 3H), 1.78 – 1.70 (m, 1H), 1.60 (dtd, *J* = 14.2, 6.1, 5.5, 3.0 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 143.93, 141.65, 128.70, 128.52, 127.55, 126.46, 123.45, 122.55, 116.63, 116.43, 56.41, 54.83, 50.59, 37.98, 37.73, 33.73, 15.53, 12.60.


7'-Chloro-*N*-(4-chlorophenyl)-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3da)^[2]



3da, 57%

The general procedure was applied to 4-bromoaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow solid (26 mg, 57% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.36 (d, *J* = 2.3 Hz, 1H), 7.12 (dd, *J* = 8.7, 3.4 Hz, 3H), 6.52 (d, *J* = 8.5 Hz, 1H), 6.34 – 6.28 (m, 2H), 4.22 (s, 1H), 4.02 (s, 1H), 2.86 (t, *J* = 8.5 Hz, 1H), 2.28 – 2.15 (m, 2H), 2.04 – 1.95 (m, 2H), 1.94 – 1.81 (m, 3H), 1.78 – 1.69 (m, 1H), 1.63 – 1.55 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 144.31, 142.07, 131.57, 130.39, 129.33, 128.90, 117.04, 116.86, 110.62, 109.69, 56.30, 54.76, 50.61, 38.03, 37.74, 33.74, 15.54, 12.59.


7'-Iodo-N-(4-iodophenyl)-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ea)^[2]



3ea, 59%

The general procedure was applied to 4-iodoaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow solid (32 mg, 59% yield). ¹H NMR (600 MHz, DMSO) δ = 7.25 (d, *J* = 8.2 Hz, 2H), 6.60 (d, *J* = 8.4 Hz, 1H), 6.51 (s, 1H), 6.35 (s, 1H), 6.24 (d, *J* = 8.3 Hz, 2H), 2.73 (t, *J* = 8.2 Hz, 1H), 2.47 (d, *J* = 9.4 Hz, 1H), 2.05 (q, *J* = 9.9 Hz, 1H), 1.92 (dt, *J* = 19.7, 8.9 Hz, 4H), 1.83 (t, *J* = 10.3 Hz, 1H), 1.71 (q, *J* = 10.2 Hz, 1H), 1.54 (q, *J* = 9.4 Hz, 1H), 1.44 (q, *J* = 8.8, 8.4 Hz, 1H). ¹³C NMR (151 MHz, DMSO) δ 145.67, 143.69, 136.54, 135.20, 133.96, 128.71, 117.51, 116.86, 78.01, 76.98, 54.74, 53.83, 50.83, 37.96, 36.14, 32.68, 15.45, 12.03.


**7'-(Trifluoromethoxy)-*N*-(4-(trifluoromethoxy)phenyl)-2',2a'-
dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-
amine (3fa)**



3fa, 33%

The general procedure was applied to 4-(trifluoromethoxy)aniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:20) to afford the title compound as a colorless liquid (15 mg, 33% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.13 (dd, *J* = 2.8, 1.0 Hz, 1H), 6.95 – 6.85 (m, 3H), 6.61 (d, *J* = 8.6 Hz, 1H), 6.39 – 6.34 (m, 2H), 4.11 (s, 2H), 2.92 – 2.85 (m, 1H), 2.31 – 2.17 (m, 2H), 2.06 – 1.96 (m, 2H), 1.96 – 1.82 (m, 3H), 1.79 – 1.70 (m, 1H), 1.67 – 1.57 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 144.02, 141.85, 141.38, 140.93, 127.83, 121.85, 120.79, 119.83, 115.94, 115.71, 56.52, 54.86, 50.60, 37.85, 37.71, 33.69, 15.46, 12.59.


Methyl 8b'-((4-(methoxycarbonyl)phenyl)amino)-2',2a',4',8b'-tetrahydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinoline]-7'-carboxylate (3ga)^[2]



3ga, 40%

The general procedure was applied to methyl 4-aminobenzoate (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:10) to afford the title compound as a white solid (16 mg, 40% yield). ¹H NMR (400 MHz, DMSO) δ = 7.63 (d, *J* = 2.1 Hz, 1H), 7.50 (dd, *J* = 14.9, 8.6 Hz, 3H), 7.20 (s, 1H), 7.09 (s, 1H), 6.69 (d, *J* = 8.6 Hz, 1H), 6.31 (d, *J* = 8.4 Hz, 2H), 3.64 (d, *J* = 7.1 Hz, 6H), 2.79 (t, *J* = 8.9 Hz, 1H), 2.55 (q, *J* = 10.6, 10.2 Hz, 1H), 2.12 – 1.96 (m, 2H), 1.94 – 1.80 (m, 4H), 1.62 (d, *J* = 7.4 Hz, 1H), 1.51 (q, *J* = 9.5 Hz, 1H), 1.31 (p, *J* = 10.0 Hz, 1H). ¹³C NMR (101 MHz, DMSO) δ = 166.66, 166.64, 150.54, 148.54, 131.50, 130.60, 129.32, 123.69, 117.55, 116.56, 114.24, 113.52, 54.81, 53.92, 51.61, 51.29, 39.05, 36.68, 33.44, 15.90, 12.29.


1-(4-((7'-Acetyl-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinoline]-8b'(4'*H*)-yl)amino)phenyl)ethan-1-one (3ha)



3ha, 29%

The general procedure was applied to 1-(4-aminophenyl)ethan-1-one (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:10) to afford the title compound as a white solid (11 mg, 29% yield). ¹H NMR (400 MHz, DMSO) δ = 7.63 (d, *J* = 2.1 Hz, 1H), 7.57 (dd, *J* = 8.6, 2.1 Hz, 1H), 7.53 (s, 1H), 7.51 (s, 1H), 7.25 (s, 1H), 7.17 (s, 1H), 6.69 (d, *J* = 8.5 Hz, 1H), 6.32 (d, *J* = 8.5 Hz, 2H), 2.81 (t, *J* = 8.9 Hz, 1H), 2.57 (q, *J* = 10.2 Hz, 1H), 2.29 (d, *J* = 5.2 Hz, 6H), 2.10 – 1.81 (m, 6H), 1.69 – 1.59 (m, 1H), 1.58 – 1.49 (m, 1H), 1.37 – 1.25 (m, 1H). ¹³C NMR (101 MHz, DMSO) δ = 195.53, 195.41, 150.61, 148.67, 130.06, 129.32, 128.30, 126.50, 125.47, 123.64, 113.84, 113.34, 54.86, 53.97, 51.22, 39.07, 36.64, 33.44, 26.24, 15.96, 12.32.


7'-Methyl-*N*-(*p*-tolyl)-2',2*a*'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8*b*'(4'*H*)-amine (3ia)^[2]



3ia, 96%

The general procedure was applied to *p*-toluidine (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a red liquid (31 mg, 96% yield). ¹H NMR (400 MHz, cdcl₃) δ = 7.20 (d, *J* = 2.0 Hz, 1H), 6.94 – 6.86 (m, 3H), 6.58 (d, *J* = 8.0 Hz, 1H), 6.47 (d, *J* = 8.4 Hz, 2H), 3.95 (s, 2H), 2.97 (t, *J* = 8.4 Hz, 1H), 2.38 – 2.30 (m, 1H), 2.22 (d, *J* = 4.4 Hz, 6H), 2.17 (dd, *J* = 11.2, 4.8 Hz, 1H), 2.06 – 1.89 (m, 4H), 1.84 (t, *J* = 8.9 Hz, 1H), 1.72 (tt, *J* = 9.5, 4.7 Hz, 1H), 1.69 – 1.58 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 143.54, 140.58, 129.38, 128.16, 128.07, 127.16, 126.97, 116.02, 115.45, 56.95, 54.89, 49.89, 37.53, 37.44, 33.76, 20.75, 20.42, 15.49, 12.73.


**7'-Methoxy-*N*-(4-methoxyphenyl)-2',2a'-dihydro-1'*H*-
spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ja)^[2]**



3ja, 97%

The general procedure was applied to 4-methoxyaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:10) to afford the title compound as a white solid (34 mg, 97% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.01 (d, *J* = 2.8 Hz, 1H), 6.70 – 6.65 (m, 3H), 6.59 (d, *J* = 8.4 Hz, 1H), 6.49 (d, *J* = 8.8 Hz, 2H), 3.70 (d, *J* = 6.2 Hz, 6H), 2.87 (t, *J* = 8.4 Hz, 1H), 2.25 (t, *J* = 9.9 Hz, 1H), 2.19 (dd, *J* = 10.0, 4.8 Hz, 1H), 1.99 (dd, *J* = 11.7, 4.1 Hz, 1H), 1.92 (ddd, *J* = 17.3, 8.3, 4.9 Hz, 2H), 1.71 (ddd, *J* = 15.2, 11.4, 7.8 Hz, 3H), 1.64 – 1.50 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 153.89, 152.72, 139.75, 137.05, 129.14, 118.04, 116.48, 114.35, 114.06, 111.52, 57.76, 55.61, 55.55, 54.98, 49.63, 37.48, 37.20, 33.60, 15.35, 12.72.


6'-Fluoro-*N*-(3-fluorophenyl)-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ka)^[2]



3ka, 31%

The general procedure was applied to 3-fluoroaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a white solid (10 mg, 31% yield). ¹H NMR (600 MHz, CDCl₃) δ = 7.19 (dd, *J* = 8.6, 6.4 Hz, 1H), 6.97 (td, *J* = 8.2, 6.8 Hz, 1H), 6.39 (td, *J* = 8.5, 2.5 Hz, 1H), 6.35 – 6.29 (m, 2H), 6.22 (ddd, *J* = 8.2, 2.3, 0.9 Hz, 1H), 6.08 (dt, *J* = 12.0, 2.4 Hz, 1H), 4.33 (s, 1H), 4.08 (s, 1H), 2.93 (t, *J* = 8.7 Hz, 1H), 2.33 – 2.25 (m, 1H), 2.19 – 2.12 (m, 1H), 2.04 (ddt, *J* = 13.0, 8.7, 4.0 Hz, 1H), 1.98 – 1.88 (m, 4H), 1.73 (dtd, *J* = 11.8, 9.6, 4.8 Hz, 1H), 1.63 – 1.57 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ = 163.32, 161.71, 147.31, 144.42, 129.77, 128.61, 122.03, 111.02, 105.88, 103.97, 101.59, 101.43, 56.05, 54.75, 50.82, 38.16, 37.84, 33.91, 15.38, 12.58.


6'-Chloro-*N*-(3-chlorophenyl)-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3la)^[2]



3la, 63%

The general procedure was applied to 3-chloroaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a white solid (23 mg, 63% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.19 – 7.13 (m, 1H), 6.94 (t, *J* = 8.1 Hz, 1H), 6.67 – 6.59 (m, 3H), 6.40 (t, *J* = 2.2 Hz, 1H), 6.28 (ddd, *J* = 8.2, 2.3, 0.9 Hz, 1H), 4.30 (s, 1H), 4.07 (s, 1H), 2.89 (t, *J* = 8.5 Hz, 1H), 2.30 – 2.21 (m, 1H), 2.16 (ddd, *J* = 11.5, 10.1, 4.5 Hz, 1H), 2.07 – 1.89 (m, 5H), 1.76 (ddt, *J* = 16.2, 9.8, 4.6 Hz, 1H), 1.67 – 1.58 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 146.53, 144.14, 134.43, 132.92, 129.78, 128.11, 125.05, 118.92, 117.53, 114.88, 114.84, 113.18, 55.94, 54.90, 50.92, 38.07, 37.70, 33.80, 15.52, 12.62.


6'-Bromo-*N*-(3-bromophenyl)-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ma)^[2]



3ma, 91%

The general procedure was applied to 3-bromoaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a white solid (41 mg, 91% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.08 (d, *J* = 8.7 Hz, 1H), 6.87 (t, *J* = 8.0 Hz, 1H), 6.81 – 6.75 (m, 3H), 6.56 (t, *J* = 2.1 Hz, 1H), 6. (dd, *J* = 7.7, 1.8 Hz, 1H), 4.28 (s, 1H), 4.06 (s, 1H), 2.88 (t, *J* = 8.530 Hz, 1H), 2.29 – 2.14 (m, 2H), 2.06 – 1.89 (m, 5H), 1.77 (ddt, *J* = 11.6, 9.2, 4.7 Hz, 1H), 1.61 (dtd, *J* = 11.8, 8.4, 2.9 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 146.63, 144.42, 132.23, 130.08, 128.34, 125.52, 122.70, 121.79, 121.05, 120.43, 117.78, 115.72, 113.49, 55.96, 54.92, 50.93, 38.07, 37.64, 33.78, 15.55, 12.63.


6'-Iodo-*N*-(3-iodophenyl)-2',2*a*'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8*b*'(4'*H*)-amine (3na)^[2]



3na, 66%

The general procedure was applied to 3-iodoaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a white solid (36 mg, 66% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.03 – 6.91 (m, 4H), 6.78 (s, 1H), 6.73 (t, *J* = 8.0 Hz, 1H), 6.33 (dd, *J* = 8.2, 2.3 Hz, 1H), 4.24 (s, 1H), 4.13 (q, *J* = 7.1 Hz, 1H), 4.05 (s, 1H), 2.87 (t, *J* = 8.5 Hz, 1H), 2.28 – 2.11 (m, 2H), 2.05 (s, 1H), 2.03 – 1.99 (m, 1H), 1.98 – 1.94 (m, 1H), 1.89 (dd, *J* = 10.3, 2.4 Hz, 1H), 1.76 (ddt, *J* = 18.2, 9.2, 4.5 Hz, 1H), 1.61 (dt, *J* = 10.4, 8.4 Hz, 2H), 1.26 (t, *J* = 7.1 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ = 146.55, 144.56, 130.26, 128.49, 127.78, 126.49, 126.28, 123.77, 123.73, 114.03, 94.73, 92.81, 55.96, 54.88, 50.98, 38.09, 37.62, 33.79, 15.59, 12.66.


6'-(Trifluoromethyl)-*N*-(3-(trifluoromethyl)phenyl)-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3oa)^[2]



3oa, 58%

The general procedure was applied to 3-(trifluoromethyl)aniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a colorless solid (25 mg, 58% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.34 (d, *J* = 8.1 Hz, 1H), 7.12 (t, *J* = 8.0 Hz, 1H), 6.95 – 6.87 (m, 3H), 6.64 (s, 1H), 6.52 (dd, *J* = 8.2, 2.4 Hz, 1H), 4.51 (s, 1H), 4.25 (s, 1H), 2.94 (t, *J* = 8.6 Hz, 1H), 2.34 – 2.22 (m, 2H), 2.13 – 2.02 (m, 2H), 2.00 – 1.91 (m, 3H), 1.78 (tdd, *J* = 14.3, 10.2, 5.0 Hz, 1H), 1.64 (dtd, *J* = 17.5, 8.9, 3.1 Hz, 2H). ¹³C NMR (101 MHz, cdcl₃) δ 145.40, 143.31, 130.93, 129.72, 129.56, 129.23, 127.35, 125.56, 122.85, 117.66, 115.14, 114.06, 111.88, 111.37, 55.97, 54.76, 51.34, 38.18, 37.70, 33.85, 15.57, 12.53.

**6'-Methoxy-*N*-(3-methoxyphenyl)-2',2a'-dihydro-1'*H*-
spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3pa)**




3pa, 70%

The general procedure was applied to 3-methoxyaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:10) to afford the title compound as a colorless liquid (25 mg, 70% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.07 (ddd, *J* = 8.2, 3.9, 1.7 Hz, 1H), 6.82 (dq, *J* = 10.0, 3.9, 3.0 Hz, 1H), 6.17 (ddd, *J* = 6.1, 3.8, 1.8 Hz, 1H), 6.11 – 6.06 (m, 1H), 6.05 – 6.01 (m, 1H), 6.01 – 5.95 (m, 1H), 5.90 (dd, *J* = 4.0, 2.1 Hz, 1H), 3.96 (d, *J* = 84.4 Hz, 2H), 3.61 (dd, *J* = 4.0, 1.8 Hz, 3H), 3.52 – 3.45 (m, 3H), 2.85 (s, 1H), 2.20 (td, *J* = 10.5, 9.9, 3.7 Hz, 1H), 2.08 – 1.97 (m, 1H), 1.93 – 1.69 (m, 5H), 1.62 – 1.53 (m, 1H), 1.51 – 1.42 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 160.24, 159.22, 147.28, 143.95, 129.45, 128.41, 119.75, 108.43, 105.05, 103.04, 101.10, 100.03, 56.24, 55.09, 54.88, 54.67, 50.52, 38.15, 37.72, 33.98, 15.31, 12.64.

The chemical structure shows a benzocyclobuta[1,2-b]pyridine core. The pyridine ring is partially hydrogenated, with NH groups at positions 1 and 5. A methyl group is attached to the nitrogen at position 1. A 4-methylphenyl group is attached to the carbon at position 4. The benzene ring fused to the pyridine has a methyl group at the 6-position.

S21


6'-Ethyl-*N*-(3-ethylphenyl)-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ra)



3ra, 29%

The general procedure was applied to 3-ethylaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow liquid (10 mg, 29% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.28 (d, *J* = 7.9 Hz, 1H), 7.05 – 6.99 (m, 1H), 6.61 (dd, *J* = 7.9, 1.7 Hz, 1H), 6.55 (d, *J* = 7.8 Hz, 1H), 6.51 (d, *J* = 1.7 Hz, 1H), 6.37 (dd, *J* = 7.8, 1.5 Hz, 2H), 4.07 (d, *J* = 88.6 Hz, 2H), 3.05 (t, *J* = 8.6 Hz, 1H), 2.60 (q, *J* = 7.6 Hz, 2H), 2.52 (q, *J* = 7.6 Hz, 2H), 2.42 (dd, *J* = 20.0, 9.9 Hz, 1H), 2.26 – 2.18 (m, 1H), 2.07 – 1.96 (m, 3H), 1.92 – 1.85 (m, 1H), 1.75 – 1.58 (m, 3H), 1.32 (s, 1H), 1.26 (t, *J* = 7.6 Hz, 3H), 1.16 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ = 145.97, 144.77, 143.50, 142.82, 128.67, 127.14, 124.99, 118.82, 117.27, 115.24, 114.52, 112.83, 56.48, 54.66, 50.38, 37.93, 37.42, 34.00, 28.93, 28.58, 15.39, 15.37, 15.27, 12.71.


**5'-Methoxy-*N*-(2-methoxyphenyl)-2',2a'-dihydro-1'*H*-
spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3sa)**



3sa, 20%

The general procedure was applied to 2-methoxyaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:40) to afford the title compound as a colorless liquid (7 mg, 20% yield). ¹H NMR (400 MHz, CDCl₃) δ = 6.99 (dd, *J* = 7.4, 1.8 Hz, 1H), 6.82 – 6.75 (m, 1H), 6.72 – 6.57 (m, 4H), 6.33 – 6.25 (m, 1H), 4.91 (s, 1H), 4.74 – 4.60 (m, 1H), 3.90 (d, *J* = 7.0 Hz, 6H), 2.97 (t, *J* = 8.6 Hz, 1H), 2.45 (ddd, *J* = 11.3, 10.0, 8.7 Hz, 1H), 2.22 (ddd, *J* = 11.4, 9.7, 4.1 Hz, 1H), 2.11 – 1.94 (m, 4H), 1.84 (q, *J* = 10.9, 10.0 Hz, 1H), 1.75 – 1.58 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ = 147.33, 146.61, 135.53, 132.90, 127.51, 120.60, 118.98, 117.32, 116.34, 113.26, 109.31, 107.56, 56.00, 55.53, 55.47, 54.11, 51.07, 38.59, 37.59, 33.82, 15.43, 12.64.


***N*-(3,4-Dimethylphenyl)-6',7'-dimethyl-2',2a'-dihydro-1'*H*-
spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ta)^[2]**



3ta, 60%

The general procedure was applied to 3,4-dimethylaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow liquid (22 mg, 60% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.13 (s, 1H), 6.84 (d, *J* = 8.1 Hz, 1H), 6.47 (s, 1H), 6.43 (d, *J* = 2.5 Hz, 1H), 6.30 (dd, *J* = 8.1, 2.5 Hz, 1H), 3.88 (s, 2H), 2.98 (t, *J* = 8.5 Hz, 1H), 2.41 – 2.33 (m, 1H), 2.20 (s, 3H), 2.15 (s, 3H), 2.13 (s, 3H), 2.12 (s, 3H), 2.01 (ddd, *J* = 8.8, 6.4, 3.9 Hz, 2H), 1.95 – 1.88 (m, 2H), 1.87 – 1.80 (m, 1H), 1.78 – 1.64 (m, 2H), 1.64 – 1.56 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 143.99, 140.73, 136.82, 135.60, 129.87, 127.72, 126.95, 125.85, 125.68, 117.86, 116.66, 113.18, 56.71, 54.80, 49.58, 37.48, 37.24, 33.81, 20.01, 19.62, 19.02, 18.70, 15.36, 12.76.


***N*-(3,4-Difluorophenyl)-6',7'-difluoro-2',2a'-dihydro-1'*H*-
spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ua)**



3ua, 69%

The general procedure was applied to 3,4-difluoroaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow solid (25 mg, 69% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.06 (dd, *J* = 11.3, 8.8 Hz, 1H), 6.90 – 6.78 (m, 1H), 6.43 (dd, *J* = 11.6, 6.8 Hz, 1H), 6.22 – 6.08 (m, 2H), 4.13 (s, 1H), 3.95 (s, 1H), 2.82 (t, *J* = 8.5 Hz, 1H), 2.22 – 2.11 (m, 2H), 2.07 – 1.91 (m, 3H), 1.88 – 1.82 (m, 2H), 1.79 – 1.72 (m, 1H), 1.64 – 1.57 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 151.57, 151.44, 150.96, 150.82, 149.14, 149.01, 148.52, 148.38, 145.33, 145.20, 144.65, 144.52, 142.96, 142.83, 142.29, 142.26, 142.24, 142.18, 142.16, 139.71, 139.69, 139.63, 139.61, 122.14, 122.10, 122.07, 117.19, 117.17, 117.01, 116.99, 115.09, 115.07, 114.91, 114.89, 110.81, 110.78, 110.76, 110.73, 104.13, 103.92, 103.68, 103.48, 56.35, 54.94, 50.58, 37.87, 33.64, 29.69, 15.31, 12.52.


6'-Chloro-*N*-(3-chloro-4-methoxyphenyl)-7'-methoxy-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3va)



3va, 31%

The general procedure was applied to 3-chloro-4-methoxyaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow liquid (13 mg, 31% yield). ¹H NMR (600 MHz, CDCl₃) δ = 6.88 (s, 1H), 6.64 (s, 1H), 6.59 (d, *J* = 8.8 Hz, 1H), 6.50 (d, *J* = 2.8 Hz, 1H), 6.23 (dd, *J* = 8.8, 2.8 Hz, 1H), 3.71 (s, 3H), 3.66 (s, 3H), 2.78 – 2.68 (m, 1H), 2.15 – 2.07 (m, 2H), 1.94 – 1.85 (m, 2H), 1.81 (dt, *J* = 12.0, 8.8 Hz, 1H), 1.73 – 1.69 (m, 2H), 1.59 – 1.46 (m, 3H). ¹³C NMR (151 MHz, CDCl₃) δ = 148.40, 147.99, 140.15, 137.60, 126.92, 118.45, 117.10, 115.18, 113.35, 111.09, 57.25, 56.82, 56.71, 55.04, 50.36, 37.82, 37.47, 33.51, 15.35, 12.69.


6'-Chloro-*N*-(3-chloro-4-ethylphenyl)-7'-ethyl-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3wa)^[2]



3wa, 32%

The general procedure was applied to 3-chloro-4-ethylaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a red liquid (13 mg, 32% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.13 (s, 1H), 6.90 (d, *J* = 8.3 Hz, 1H), 6.67 (s, 1H), 6.49 (d, *J* = 2.5 Hz, 1H), 6.31 (dd, *J* = 8.3, 2.4 Hz, 1H), 4.02 (d, *J* = 70.7 Hz, 2H), 2.90 (t, *J* = 8.5 Hz, 1H), 2.59 (p, *J* = 7.3 Hz, 4H), 2.28 (q, *J* = 10.0 Hz, 1H), 2.16 (td, *J* = 11.1, 10.6, 4.5 Hz, 1H), 2.04 – 1.85 (m, 5H), 1.74 (ddd, *J* = 14.1, 9.2, 4.7 Hz, 1H), 1.67 – 1.57 (m, 2H), 1.13 (dt, *J* = 19.2, 7.5 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ = 144.60, 141.99, 133.72, 132.30, 131.77, 130.53, 129.48, 127.65, 126.19, 116.09, 115.60, 114.26, 56.45, 54.95, 50.46, 37.71, 37.59, 33.69, 26.04, 25.73, 15.44, 14.65, 14.38, 12.68.


6'-Chloro-*N*-(3-chloro-4-methylphenyl)-7'-methyl-2',2a'-dihydro-1'*H*-spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3xa)



3xa, 46%

The general procedure was applied to 3-chloro-4-methylaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a yellow solid (18 mg, 46% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.11 (s, 1H), 6.88 (d, *J* = 8.2 Hz, 1H), 6.67 (s, 1H), 6.48 (d, *J* = 2.4 Hz, 1H), 6.26 (dd, *J* = 8.3, 2.5 Hz, 1H), 4.01 (s, 2H), 2.86 (t, *J* = 8.5 Hz, 1H), 2.19 (d, *J* = 5.3 Hz, 8H), 2.04 – 1.85 (m, 5H), 1.74 (ddt, *J* = 14.0, 9.3, 4.7 Hz, 1H), 1.61 (t, *J* = 8.7 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 144.58, 142.01, 134.28, 132.88, 130.87, 128.76, 125.96, 125.82, 124.66, 115.77, 115.40, 113.93, 56.26, 54.99, 50.47, 37.79, 37.65, 33.70, 19.17, 18.84, 15.47, 12.65.


***N*-(3,5-Difluorophenyl)-6',8'-difluoro-2',2a'-dihydro-1'*H*-
spiro[cyclobutane-1,3'-cyclobuta[*c*]quinolin]-8b'(4'*H*)-amine (3ya)^[2]**



3ya, 39%

The general procedure was applied to 3,5-difluoroaniline (0.2 mmol), cyclobutanone oxime (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:60) to afford the title compound as a white solid (12 mg, 39% yield). ¹H NMR (400 MHz, CDCl₃) δ = 6.14 – 5.99 (m, 3H), 5.96 – 5.82 (m, 2H), 4.53 (s, 1H), 4.39 (s, 1H), 2.97 – 2.90 (m, 1H), 2.43 – 2.29 (m, 2H), 2.08 (td, *J* = 7.9, 3.8 Hz, 3H), 1.99 – 1.90 (m, 2H), 1.74 – 1.60 (m, 2H), 1.52 – 1.44 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ = 164.85, 164.69, 164.08, 163.99, 163.91, 163.84, 162.43, 162.28, 161.64, 161.52, 161.48, 161.37, 147.80, 147.67, 147.54, 145.62, 145.49, 145.39, 105.80, 105.68, 105.65, 97.27, 97.18, 97.06, 96.98, 96.15, 96.12, 95.91, 95.88, 93.55, 93.29, 93.03, 92.59, 92.33, 92.07, 53.93, 53.59, 50.26, 38.93, 35.28, 34.78, 16.44, 12.29.

***N*-Phenyl-1'*H*,4'*H*-spiro[oxetane-3,3'-oxeto[2,3-*c*]quinolin]-8b'(2a'*H*)-amine (3ab)**




3ab, 76%

The general procedure was applied to aniline (0.2 mmol), oxetan-3-one (0.4 mmol), $\text{Cu}(\text{CF}_3\text{COO})_2$ (11.58 mg, 0.04 mmol), n-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:5) to afford the title compound as a white solid (22 mg, 76% yield). ^1H NMR (400 MHz, DMSO) δ = 7.00 (ddd, J = 19.9, 8.2, 6.8 Hz, 4H), 6.94 – 6.86 (m, 2H), 6.77 (s, 1H), 6.59 (t, J = 7.4 Hz, 1H), 6.52 (t, J = 7.3 Hz, 1H), 6.21 (d, J = 7.6 Hz, 2H), 5.01 (d, J = 2.0 Hz, 1H), 4.75 (d, J = 5.8 Hz, 1H), 4.57 (d, J = 6.5 Hz, 1H), 4.50 (d, J = 6.6 Hz, 1H), 4.36 (d, J = 6.0 Hz, 1H), 4.20 (dd, J = 16.1, 5.9 Hz, 2H). ^{13}C NMR (101 MHz, DMSO) δ = 145.94, 143.71, 143.66, 129.19, 128.33, 125.41, 124.37, 118.88, 117.16, 116.35, 116.32, 114.24, 92.78, 82.16, 81.21, 78.21, 56.80, 55.63.

***N*-Phenyl-1'*H*,4'*H*-spiro[thietane-3,3'-thieto[2,3-*c*]quinolin]-**


8b'(2a'*H*)-amine (3ac)^[2]



3ac, 78%

The general procedure was applied to aniline (0.2 mmol), thietan-3-one (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:10) to afford the title compound as a white solid (25 mg, 78% yield). ¹H NMR (600 MHz, CDCl₃) δ = 7.31 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.11 (dd, *J* = 8.8, 7.4 Hz, 3H), 6.80 (td, *J* = 7.5, 1.2 Hz, 1H), 6.73 (t, *J* = 7.4 Hz, 2H), 6.64 (d, *J* = 7.5 Hz, 2H), 4.96 (s, 1H), 4.58 (s, 1H), 4.35 (s, 1H), 3.72 (d, *J* = 9.6 Hz, 1H), 3.14 (d, *J* = 10.3 Hz, 1H), 3.07 (d, *J* = 9.6 Hz, 1H), 2.99 (dd, *J* = 11.7, 2.2 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ = 144.63, 141.16, 129.48, 128.95, 127.96, 126.23, 120.77, 119.15, 116.74, 115.55, 61.02, 59.37, 56.41, 40.56, 39.12, 37.71.


Dimethyl 8b'-(phenylamino)-2',2a',4',8b'-tetrahydro-1'H-spiro[cyclobutane-1,3'-cyclobuta[c]quinoline]-2',3-dicarboxylate
(3ad)^[2]



3ad, 37%

The general procedure was applied to aniline (0.2 mmol), methyl 3-oxocyclobutane-1-carboxylate (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:10) to afford the title compound as a colorless liquid (15 mg, 37% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.40 (d, *J* = 7.7 Hz, 1H), 7.13 – 7.02 (m, 3H), 6.79 (t, *J* = 7.5 Hz, 1H), 6.70 (dd, *J* = 14.6, 7.6 Hz, 2H), 6.46 (d, *J* = 8.7 Hz, 2H), 4.34 (s, 1H), 4.11 (s, 1H), 3.73 (s, 3H), 3.61 (s, 3H), 3.18 – 3.06 (m, 2H), 2.84 (dt, *J* = 9.1, 6.9 Hz, 1H), 2.69 – 2.56 (m, 2H), 2.35 (dd, *J* = 12.1, 9.6 Hz, 1H), 2.26 – 2.20 (m, 1H), 2.14 (d, *J* = 8.6 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ = 175.94, 175.30, 145.41, 142.39, 128.88, 128.01, 127.71, 126.78, 120.02, 118.35, 116.26, 115.85, 56.53, 54.12, 52.91, 52.11, 51.90, 40.03, 39.80, 35.69, 32.58, 30.56.

Diethyl 8b'-(phenylamino)-2',2a',4',8b'-tetrahydro-1'H-spiro[cyclobutane-1,3'-cyclobuta[c]quinoline]-2',3-dicarboxylate (3ae)




3ae, 40%

The general procedure was applied to aniline (0.2 mmol), 3-oxocyclobutyl propionate (0.4 mmol), Cu(CF₃COO)₂ (11.58 mg, 0.04 mmol), *n*-hexane (2 mL) at 80 °C for 12 h. The crude product was purified by column chromatography on neutral alumina (EtOAc/PE 1:10) to afford the title compound as a white solid (17 mg, 40% yield). ¹H NMR (400 MHz, CDCl₃) δ = 7.37 (d, *J* = 7.8 Hz, 1H), 7.12 – 7.01 (m, 3H), 6.76 (t, *J* = 7.5 Hz, 1H), 6.73 – 6.65 (m, 2H), 6.52 – 6.45 (m, 2H), 4.49 (s, 1H), 4.32 (s, 1H), 4.21 – 4.09 (m, 4H), 3.07 (d, *J* = 7.1 Hz, 1H), 2.87 – 2.79 (m, 1H), 2.75 (q, *J* = 7.6 Hz, 1H), 2.67 (dd, *J* = 11.8, 7.5 Hz, 1H), 2.47 (ddd, *J* = 12.3, 8.8, 3.1 Hz, 1H), 2.38 (dd, *J* = 11.8, 9.3 Hz, 1H), 2.28 – 2.18 (m, 2H), 2.05 (dd, *J* = 12.0, 7.5 Hz, 1H), 1.26 (dd, *J* = 15.5, 6.9 Hz, 7H). ¹³C NMR (101 MHz, CDCl₃) δ = 176.35, 175.56, 145.46, 142.17, 128.93, 127.83, 126.96, 126.93, 119.69, 118.24, 116.10, 115.70, 60.84, 60.79, 55.55, 54.02, 51.48, 40.64, 40.46, 36.12, 32.81, 29.65, 14.23, 14.19.

Single-crystal data of compound 3aa

Datablock jqq01 - ellipsoid plot



Structure factors have been supplied for datablock(s) jqq01

No syntax errors found. CIF dictionary Interpreting this report

Bond precision:	C-C = 0.0248 Å	Wavelength=0.71073	
Cell:	a=10.5820 (15) alpha=90	b=10.5820 (15) beta=90	c=28.192 (4) gamma=120
Temperature:	298 K		
	Calculated	Reported	
Volume	2734.0 (9)	2734.0 (9)	
Space group	P 31	P 31	
Hall group	P 31	P 31	
Moiety formula	C20 Br2 N2	2 (Br2 C20 N2)	
Sum formula	C20 Br2 N2	C40 Br4 N4	
Mr	428.02	856.08	
Dx, g cm-3	1.560	1.560	
Z	6	3	
Mu (mm-1)	4.448	4.448	
F000	1224.0	1224.0	
F000'	1221.11		
h, k, lmax	13, 13, 36	13, 13, 36	
Nref	8446 [4223]	6917	
Tmin, Tmax	0.566, 0.641	0.422, 0.746	
Tmin'	0.555		

Data completeness= 1.64/0.82 Theta (max)= 27.568

[illegible]

The following ALERTS were generated. Each ALERT has the format
test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.

● Alert level B

PLAT241_ALERT_2_B High 'MainMol' Ueq as Compared to Neighbors of C9 Check
PLAT341_ALERT_3_B Low Bond Precision on C-C Bonds 0.02477 Ang.

● Alert level C

PLAT041_ALERT_1_C Calc. and Reported SumFormula Strings Differ Please Check
Calc: C20 Br2 N2
Rep.: C40 Br4 N4
PLAT042_ALERT_1_C Calc. and Reported MoietyFormula Strings Differ Please Check
Calc: C20 Br2 N2
Rep.: 2(Br2 C20 N2)
PLAT057_ALERT_3_C Correction for Absorption Required RT(exp) ... 1.13 Do !
PLAT241_ALERT_2_C High 'MainMol' Ueq as Compared to Neighbors of N2 Check
PLAT241_ALERT_2_C High 'MainMol' Ueq as Compared to Neighbors of C19 Check
PLAT241_ALERT_2_C High 'MainMol' Ueq as Compared to Neighbors of C33 Check
PLAT242_ALERT_2_C Low 'MainMol' Ueq as Compared to Neighbors of C8 Check
PLAT242_ALERT_2_C Low 'MainMol' Ueq as Compared to Neighbors of C10 Check
PLAT242_ALERT_2_C Low 'MainMol' Ueq as Compared to Neighbors of C16 Check
PLAT906_ALERT_3_C Large K Value in the Analysis of Variance 4.669 Check
PLAT906_ALERT_3_C Large K Value in the Analysis of Variance 2.391 Check
PLAT911_ALERT_3_C Missing FCF Refl Between Thmin & STh/L= 0.600 62 Report
-6 11 0, 5 6 1, 0 1 2, 5 6 2, -6 10 6, -5 10 8,
-4 10 9, -3 10 9, -8 9 11, -7 9 11, -11 7 12, -8 9 12,
-7 9 12, -5 9 12, -7 9 13, -6 9 13, -3 9 13, -10 7 14,
-8 8 14, -6 9 14, -9 7 15, -7 8 15, -6 8 15, -5 8 15,
-8 7 16, -4 7 16, -7 8 16, -6 8 16, -5 8 16, -4 8 16,
-8 7 17, -7 7 17, -4 7 17, -6 8 17, -5 8 17, -4 8 17,
-8 6 18, -7 7 18, -6 7 18, -4 7 18, -5 8 18, -4 8 18,
-6 7 19, -5 7 19, -4 7 19, -3 7 19, -1 7 19, -5 8 19,
-4 8 19, -5 7 20, -4 7 20, -6 6 21, -5 6 21, -6 6 22,
-5 6 22, -2 6 22, -6 5 23, -5 6 23, -6 5 24, -5 5 24,
0 5 25, 0 0 30,
PLAT915_ALERT_3_C No Flack x Check Done: Low Friedel Pair Coverage 66 %

● Alert level G

PLAT002_ALERT_2_G Number of Distance or Angle Restraints on AtSite 16 Note
PLAT040_ALERT_1_G No H-atoms in this Carbon Containing Compound .. Please Check
PLAT045_ALERT_1_G Calculated and Reported Z Differ by a Factor ... 2 Check
PLAT172_ALERT_4_G The CIF-Embedded .res File Contains DFIX Records 4 Report
PLAT850_ALERT_4_G Check Flack Parameter Exact Value 0.00 with s.u. 0.02 Check
PLAT860_ALERT_3_G Number of Least-Squares Restraints 9 Note
PLAT910_ALERT_3_G Missing # of FCF Reflection(s) Below Theta(Min). 3 Note
0 1 0, -1 1 1, 0 0 3,
PLAT912_ALERT_4_G Missing # of FCF Reflections Above STh/L= 0.600 21 Note
PLAT933_ALERT_2_G Number of HKL-OMIT Records in Embedded .res File 2 Note
0 1 2, -1 1 -2,
PLAT941_ALERT_3_G Average HKL Measurement Multiplicity 2.8 Low
PLAT969_ALERT_5_G The 'Henn et al.' R-Factor-gap value 1.245 Note

6. References

- [1] Olive, G.; Le Moigne, F.; Mercier, A.; Rockenbauer, A.; Tordo, P. *J. Org. Chem.* **1998**, *63*, 9095.
- [2] Chen, C.; Wang, Z.; Wang, S.; Xu, L.; Zeng, X. *Org. Lett.* **2023**, *25*, 4241.

7. ^1H and ^{13}C NMR spectra




Figure S1. ^1H (400 MHz, CDCl_3) and ^{13}C (101 MHz, CDCl_3) NMR spectra for compound **3aa**




Figure S2. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ba**




Figure S3. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ca**




Figure S4. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3da**




Figure S6. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3fa**




Figure S7. ¹H (400 MHz, DMSO) and ¹³C (101 MHz, DMSO) NMR spectra for compound **3ga**




Figure S8. ¹H (400 MHz, DMSO) and ¹³C (101 MHz, DMSO) NMR spectra for compound **3ha**




Figure S9. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ia**




Figure S10. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3Ja**




Figure S11. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ka**




Figure S12. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3la**




Figure S13. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ma**




Figure S14. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3na**




Figure S15. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3oa**




Figure S16. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3pa**




Figure S17. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3qa**




Figure S18. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ra**




Figure S19. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3sa**




Figure S20. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ta**




Figure S21. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ua**




Figure S22. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3va**




Figure S23. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3wa**




Figure S24. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3xa**




Figure S25. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ya**




Figure S26. ¹H (400 MHz, DMSO) and ¹³C (101 MHz, DMSO) NMR spectra for compound **3ab**




Figure S27. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ac**




Figure S28. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ad**




Figure S28. ¹H (400 MHz, CDCl₃) and ¹³C (101 MHz, CDCl₃) NMR spectra for compound **3ad**